MacroGenics has been granted a patent for compounds targeting IL23A and BAFF, with methods for suppressing inflammatory responses. The patent covers specific polypeptide compositions and their use in treating subjects in need. GlobalData’s report on MacroGenics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MacroGenics, Personalized cancer vaccines was a key innovation area identified from patents. MacroGenics's grant share as of February 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for compounds targeting il23a and baff
A recently granted patent (Publication Number: US11884744B2) discloses a method for suppressing an inflammatory response in a subject by administering a compound comprising specific polypeptides. The method involves the administration of a compound consisting of a first polypeptide and a second polypeptide, each with distinct characteristics. The first polypeptide includes a light chain variable domain of a first immunoglobulin (VL1) specific for a first target protein, a heavy chain variable domain of a second immunoglobulin (VH2) specific for a second target protein, and other specified regions. The second polypeptide comprises a light chain variable domain of the second immunoglobulin (VL2) specific for the second target protein and a heavy chain variable domain of the first immunoglobulin (VH1) specific for the first target protein. The method aims to suppress inflammatory responses by utilizing the unique binding properties of the polypeptides to target specific proteins like B-cell activating factor (BAFF) and Interleukin-23A (IL-23A).
Furthermore, the patent details various specific sequences and linkers that can be used in the polypeptides to achieve the desired suppression of inflammatory responses. The method involves the association of the first and second polypeptides via disulfide bonds and the formation of a tetravalent molecule to effectively target the specified proteins. The patent also outlines the amino acid sequences of the polypeptides, including specific sequences for the hinge region, heavy chain constant regions, and linkers. By utilizing these specific sequences and configurations, the method aims to provide a targeted approach for suppressing inflammatory responses in subjects in need, particularly those with inflammatory or autoimmune conditions such as systemic lupus erythematosus, rheumatoid arthritis, and psoriasis, among others.
To know more about GlobalData’s detailed insights on MacroGenics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
